Background: Psoriasis vulgaris (PV) is a chronic proliferative inflammatory dermal disease. Orosomucoid (ORM) is an acute phase protein (APP) primarily formed in the liver. Novel research revealed urinary orosomucoid (uORM) as a more sensitive, noninvasive biomarker of inflammatory activation compared to serum ORM (se-ORM).
Objective: To investigate the role of uORM as a surrogate marker for psoriasis and to correlate its urinary values with the PV severity. Patients and Methods: This was a case-control study, comprised 50 cases with confirmed diagnosis of psoriasis and control group included 50 healthy controls. The included cases were classified based on PASI score into; mild PV (≤10), moderate PV (>10 -<20) and severe PV (≥20). Morning urine samples were acquired from all cases and controls to measure urinary ORM.
Results: The AUC for uORM A in differentiating cases from control was fair with the best detected cutoff point was 53.18 yielding sensitivity of 74% and specificity 58%, and for uORM A/creatinine in differentiating cases from control was fair with the best detected cutoff point was 0.293 yielding sensitivity of 70% and specificity 52%. There was a statistically significant higher median uORM A, uORM A/ creatinine among severe cases than mild and, moderate cases.
Conclusions: A highly sensitive, inexpensive, and easily available noninvasive biomarker, uORM demonstrates itself ability to become a new inflammatory marker in PV offering further data on disease severity and progression.